These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Bifunctional aptasensor based on novel two-dimensional nanocomposite of MoS2 quantum dots and g-C3N4 nanosheets decorated with chitosan-stabilized Au nanoparticles for selectively detecting prostate specific antigen.
    Author: Duan F, Zhang S, Yang L, Zhang Z, He L, Wang M.
    Journal: Anal Chim Acta; 2018 Dec 07; 1036():121-132. PubMed ID: 30253822.
    Abstract:
    A novel nanostructured biosensing platform was designed based on two-dimensional (2D) nanocomposite of graphitic carbon nitride (g-C3N4) nanosheets and MoS2 quantum dots (MoS2 QDs), followed by decoration with chitosan-stabilized Au nanoparticles (CS-AuNPs) (denoted as MoS2QDs@g-C3N4@CS-AuNPs), of which CS-AuNPs were prepared by plasma enhanced-chemical vapor deposition. Owning to the good surface plasmon performance of the CS-AuNPs and excellent electrochemical activity of MoS2QDs@g-C3N4 nanosheets, the as-obtained 2D MoS2QDs@g-C3N4@CS-AuNPs nanocomposite was simultaneously explored to construct both surface plasmon resonance spectroscopy (SPR) sensor and electrochemical aptasensor. The MoS2QDs@g-C3N4@CS-AuNPs-based aptasensor shows strong bio-binding affinity toward the prostate specific antigen (PSA) targeted aptamer strands as compared to the individual component, including MoS2 QDs, g-C3N4, and CS-AuNPs. When detecting PSA, the low limit of detection (LOD) of 0.71 pg mL-1 deduced by electrochemical aptasensor is three orders of magnitude lower than that deduced by SPR sensor (0.77 ng mL-1). As expected, both SPR sensor and electrochemical aptasensor demonstrate good selectivity, highly stability, acceptable reproducibility, and well consistent applicability in human serum. The satisfactory results suggest potential application of the MoS2QDs@g-C3N4@CS-AuNPs in bifunctional biosensing fields and clinical monitoring of cancer markers.
    [Abstract] [Full Text] [Related] [New Search]